Nab-paclitaxel and gemcitabine combating pancreatic cancer

Share :
Published: 12 Oct 2012
Views: 5670
Dr Michel Ducreux – Institut Gustave Roussy, Paris, France

Dr Michel Ducreux talks to ecancer at ESMO 2012 in Vienna about emerging therapies for pancreatic cancer.


The prognosis for pancreatic cancer is often very poor with overall survival averaging 6 months with metastasis.


Dr Ducreux discuss on going trials that are testing the new compounds nab-paclitaxel and gemcitabine against the standard treatments. In addition the compund TH302, which fights against the cells even with hypoxia, was tested in comination with gemcitabine.


Filming supported by Amgen